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Abstract 
A 44-year-old woman presented with lower abdominal pain and bilateral ovarian masses 
on ultrasound. Exploratory laparotomy revealed extensive peritoneal and intra-
abdominal disease and an abnormal appendix. Bilateral salpingo-oophorectomy, 
infracolic omentectomy, ileocolic resection and primary anastomosis were performed. 
Final pathology revealed a primary appendiceal adenocarcinoma, poorly differentiated, 
of signet ring cell type. CT scan postoperatively revealed gross residual disease. The 
patient was treated with FOLFOX chemotherapy combined with bevacizumab. Repeat CT 
scan showed a decrease in residual disease and the patient clinically improved. After her 
treatment  has been continued for 13 months, she remains clinically well and her CT scan 
shows sustained disease stability. Disseminated appendiceal carcinoma is generally 
considered to be refractory to 5-FU-based chemotherapy and, to our knowledge, this is 
the first reported case of a patient with appendiceal adenocarcinoma demonstrating 
clinical benefit and sustained stability of disease with combination chemotherapy plus 
bevacizumab. 
 
Case Report 
A 44-year-old woman with a history of endometriosis, multiple Cesarean sections, depression and 
tubal ligation presented with lower abdominal pain. Ultrasound revealed bilateral ovarian masses. 
Laparoscopy was performed and biopsy of peritoneal disease revealed a mucin-producing 
adenocarcinoma. The patient was taken to the operating room in February 2008 for an exploratory 
laparotomy with the presumptive diagnosis of ovarian carcinoma. There was extensive peritoneal and 
intra-abdominal disease and the appendix was abnormal. Bilateral salpingo-oophorectomy, infracolic  
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omentectomy, ileocolic resection and primary anastomosis were performed. Final pathology revealed a 
primary appendiceal adenocarcinoma, poorly differentiated, of signet ring cell type (fig. 1, fig. 2). There 
was involvement of both ovaries, the right fallopian tube, right peritubular soft tissue and omentum; 
none of the 14 resected lymph nodes were involved. The patient developed a partial small bowel 
obstruction postoperatively which resolved with conservative management. 
A postoperative CT scan in March 2008 revealed gross residual disease over the serosal surfaces of 
the pelvic organs and small nodules in the upper abdomen possibly representing early carcinomatosis. 
Having recovered well from surgery, the patient was offered palliative FOLFOX chemotherapy. She was 
also offered bevacizumab based on data showing efficacy in metastatic colon cancer. She began these 
therapies in March 2008. 
Repeat CT scan following 6 cycles of chemotherapy revealed a decrease in the size and number of 
foci of peritoneal carcinomatosis. The patient was tolerating therapy well and underwent another 6 
cycles of chemotherapy before further CT scanning in August 2008, which showed stability of disease. 
After 14 cycles, she developed peripheral neuropathy necessitating discontinuation of the oxaliplatin. 
Repeat CT scanning in December 2008 and March 2009 confirmed stability of disease (fig. 3) and the 
patient continues to tolerate treatment well. 
Discussion 
Appendiceal tumors are rare neoplasms that often present with symptoms of acute 
appendicitis or are discovered incidentally during surgery for another indication [1, 2]. In 
a review of 7,970 patients with appendectomies, 74 were found to have appendiceal 
tumors (incidence of 0.9%) ranging from benign to malignant [1]. The reported age-
adjusted incidence of cancer of the appendix is 0.12 cases per 1,000,000 people per year 
[3]. Adenocarcinomas of the appendix represent an unusual variant of colon cancer and 
fall into one of three histologic categories. The most common is the mucinous type, 
followed by the intestinal or colonic type, and the least common is signet ring cell 
adenocarcinoma, which is considered to be the most virulent and is associated with a 
poor prognosis [3]. Adenocarcinoma of the appendix is the most frequently 
spontaneously perforating carcinoma of the gastrointestinal tract [2, 4] and is commonly 
associated with synchronous or metachronous tumors, particularly of the gastrointestinal 
tract [2]. 
Standard treatment for a localized appendiceal adenocarcinoma is a right 
hemicolectomy [1, 2, 5]. The role for adjuvant chemotherapy is controversial and there 
are no controlled data regarding the efficacy of chemotherapy following resection of 
localized disease. The role of adjuvant radiotherapy is also unclear due to the lack of 
randomized data. In one study, the overall 5-year survival for patients with 
adenocarcinoma of the appendix was only 55% [2], leading some medical oncologists to 
extrapolate from the data on colorectal cancer and consider adjuvant treatment with 5-
FU-based chemotherapy. 
For patients with disseminated appendiceal adenocarcinoma, the optimal treatment is 
unclear. These tumors are generally considered to be refractory to 5-FU-based 
chemotherapy. However, there is at least one case report of a patient with metastatic 
adenocarcinoid (histological features of both adenocarcinoma and carcinoid) 
demonstrating a complete and persistent response to FOLFOX-4 [6]. There is also a case 
report of a patient with hybrid histology (features of both disseminated peritoneal 
adenomucinosis and peritoneal mucinous carcinomatosis) and pseudomyxoma peritonei, 
previously treated with cytoreduction and intraperitoneal hyperthermic chemotherapy, 
demonstrating an objective response to capecitabine [7].  
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Aggressive cytoreduction and intraperitoneal hyperthermic chemotherapy (IPHC) for 
secondary peritoneal carcinomatosis have been used in several centers, although there is 
only one published prospective randomized trial [8]. 105 patients with peritoneal 
carcinomatosis from appendiceal or colorectal cancer were randomly assigned to either 
standard treatment consisting of systemic chemotherapy (fluorouracil-leucovorin) with 
or without palliative surgery or experimental therapy consisting of aggressive 
cytoreduction with IPHC followed by the same systemic chemotherapy regime. The 
median survival at a median follow-up of 21.6 months was significantly longer in the 
IPHC group (22.3 vs. 12.6 months, p = 0.032); the treatment-related mortality in the 
IPHC arm was 8% [8]. Several other institutions have published their experience with this 
aggressive treatment, but appendiceal cancers have generally constituted the minority of 
cases, and these single institution series represent highly selected patient populations [9, 
10]. 
To our knowledge, this is the first reported case of a patient with appendiceal 
adenocarcinoma demonstrating sustained stable disease and clinical benefit with 
combination chemotherapy plus bevacizumab. 
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Fig. 1. Low-power view of poorly differentiated mucinous adenocarcinoma in the wall of the appendix 
with lakes of mucin (hematoxylin and eosin, original magnification ×40). 
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Fig. 2. High-power view of the signet ring cells (hematoxylin and eosin, original magnification ×400). 
 
 
 
Fig. 3. CT scan images from March 2008 (left) and December 2008 (right) with peritoneal disease on 
the surface of the uterus, in the midline and left upper quadrant omentum. 
 
  
Case Rep Oncol 2009;2:111–115 
DOI: 10.1159/000229245 
Published online: July 17, 2009  © 2009 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
 
 
115
References 
1  Connor S, Hanna G, Frizelle F: Appendiceal tumors: retrospective 
clinicopathologic analysis of appendiceal tumors from 7,970 appendectomies. Dis 
Colon Rectum 1998;41:75–80. 
2  Nitecki S, Wolff B, Schlinkert R, Sarr M: The natural history of surgically treated 
primary adenocarcinoma of the appendix. Ann Surg 1994;219:51–57. 
3  McCusker M, Coté T, Clegg L, Sobin L: Primary malignant neoplasms of the 
appendix: a population-based study from the surveillance, epidemiology and end-
results program, 1973–1998. Cancer 2002;94:3307–3312. 
4  Cerame M: A 25-year review of adenocarcinoma of the appendix: a frequently 
perforating carcinoma. Dis Colon Rectum 1988;31:145–150. 
5  Ito H, Osteen R, Bleday R, Zinner M, Ashley S, Whang E: Appendiceal 
adenocarcinoma: long-term outcomes after surgical therapy. Dis Colon Rectum 
2004;47:474–480. 
6  Garin L, Corbinais S, Boucher E, Blanchot J, Le Guilcher P, Raoul J: 
Adenocarcinoid of the appendix vermiformis: complete and persistent remission 
after chemotherapy (folfox) of a metastatic case. Dig Dis Sci 2002;47:2760–2762. 
7  Levitz J, Sugarbaker P, Lichtman S, Brun E: Unusual abdominal tumors, case 1. 
Pseudomyxoma peritonei: response to capecitabine. J Clin Oncol 2004;22:1518–
1520. 
8  Verwaal V, van Ruth S, de Bree E, van Slooten G, van Tinteren H, Boot H, 
Zoetmulder F: Randomized trial of cytoreduction and hyperthermic 
intraperitoneal chemotherapy versus systemic chemotherapy and palliative 
surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin 
Oncol 2003;21:3737–3743. 
9  Loggie B, Fleming R, McQuellon R, Russell G, Geisinger K: Cytoreductive surgery 
with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal 
cancer of gastrointestinal origin. Am Surg 2000;66:561–568. 
10  Culliford A, Brooks A, Sharma S, Saltz L, Schwartz G, O’Reilly E, Ilson D, 
Kemeny N, Kelsen D, Guillem J, Wong W, Cohen A, Paty P: Surgical debulking 
and intraperitoneal chemotherapy for established peritoneal metastases from 
colon and appendix cancer. Ann Surg Oncol 2001;8:787–795. 
 